...
机译:血红素氧合酶-1抑制硼替佐米对多发性骨髓瘤细胞中的4月NF-κB-CCL3信号通路的抑制作用:多种骨髓瘤中的硼佐米耐药强制
Department of HematologyAffiliated Hospital of Medical UniversityGuiyang China;
Department of HematologyAffiliated Hospital of Medical UniversityGuiyang China;
Department of HematologyAffiliated Hospital of Medical UniversityGuiyang China;
Department of HematologyAffiliated Hospital of Medical UniversityGuiyang China;
Department of PharmacyThe Affiliated Hospital of Guizhou Medical UniversityGuiyang China;
Department of HematologyAffiliated Hospital of North Sichuan Medical CollegeNanchong China;
Department of HematologyAffiliated Hospital of Medical UniversityGuiyang China;
Department of HematologyAffiliated Hospital of Medical UniversityGuiyang China;
Department of HematologyAffiliated Hospital of Medical UniversityGuiyang China;
Department of HematologyAffiliated Hospital of Medical UniversityGuiyang China;
Department of HematologyAffiliated Hospital of Medical UniversityGuiyang China;
April; bortezomib (BTZ); heme oxygenase‐1 (HO‐1); multiple myeloma (MM); NF‐kappa B (NF‐κB); osteoclast (OCs); targeted therapy;
机译:血红素氧合酶-1抑制硼替佐米对多发性骨髓瘤细胞中的4月NF-κB-CCL3信号通路的抑制作用:多种骨髓瘤中的硼佐米耐药强制
机译:通过抑制多发性骨髓瘤中的NF-κB信号传导途径抑制Nortezomib酶USP7克服脱硫酶USP7
机译:通过抑制多种骨髓瘤中的NF-κB信号通路来抑制脱氢素酶USP7克服了硼齐佐米的电阻
机译:Bortezomib抗性多发性骨髓瘤的初步大规模定量蛋白质组学分析
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:蛋白激酶CK2抑制下调NF-κB和STAT3的生存途径增强细胞蛋白毒性应激并协同增强硼替佐米对多发性骨髓瘤和套细胞淋巴瘤细胞的细胞毒作用。
机译:蛋白激酶CK2抑制下调NF-κB和STAT3的生存途径,增强细胞蛋白毒性应激并协同增强硼替佐米对多发性骨髓瘤和套细胞淋巴瘤细胞的细胞毒作用。